Table 1.
Patient's characteristics
| Patient number | Sex | Age (years) | Diagnosis | Primary radiotherapy dose/fraction | Re-irradiation dose/fraction | Re-irradiation site and tumor size (cm) | Radiotherapy interval (weeks) | Began bevacizumab to re-irrediation day 1 (weeks) | Dexamethasone and mannitol before bevacizumab (weeks)* |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Male | 70 | Adenoid cystic | 56 Gy/25 f | 25 Gy/5 f | Temporal lobe (4×2.5) | 103 | 25.6 | 7.1 |
| carcinoma | |||||||||
| 2 | Male | 54 | Colon cancer | 40 Gy/20 f | 16 Gy/1 f | Parietal lobe (1.5×1.2) | 6 | 61 | 10.7 |
| Temporal lobe (1.2×1.0) Cerebella (1.0×1.0) | |||||||||
| 3 | Female | 64 | Esophageal | 40 Gy/20 f | 17 Gy/1 f | Occipital lobe (3.0×2) | 26 | 0.6 | 3.4 |
| cancer | |||||||||
| 4 | Female | 48 | Glioblastoma | 63 Gy/35 f | 25/5 f | Frontal lobe (5.0×3.5) | 138 | 18.1 | 11.7 |
| 5 | Male | 30 | Anaplastic | 59.4/33 f | 24/5 f | Frontal horns of lateral | 283.3 | 1.3 | 4.1 |
| astrocytoma | ventricles (5.0×3.0) | ||||||||
| 6 | Male | 62 | Glioblastoma | 60 Gy/30 f | 12 Gy/3 f | Occipital lobe (3.0×1.5) | 13.7 | 4.9 | 6.6 |
| 7 | Male | 51 | Glioblastoma | 60 Gy/30 f | 50.4 Gy/28 f | Frontal lobe (4.5×3.0) | 112 | 4.6 | 1.9 |
| 8 | Male | 55 | SCLC brain | 40 Gy/20 f | 16 Gy/1 f | Parietal lobe (3.0×2.0) | 38.4 | 11.7 | 9.3 |
| metastases | |||||||||
| 9 | Male | 60 | Anaplastic | 60 Gy/30 f | 24 Gy/5 f | Occipital lobe (3.5×3.2) | 25.9 | 65.7 | 12.9 |
| astrocytoma | |||||||||
| 10 | Male | 74 | Glioblastoma | 50.4 Gy/28 f | 10 Gy/1 f | Temporal insula (4.0×3.0) | 7.3 | 3.1 | 2.1 |
*The dose of dexamethasone was 5 mg, 1–2 times/day, and the dose of mannitol was 125 ml, 2–4 times/day. SCLC: Small cell lung cancer.